Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

Patient-reported Outcomes With Etoricoxib in Real Life

The purpose of this study is to collect disease burden of OA and the effectiveness and patient satisfaction of treatment by Etoricoxib in the normal practice setting.

Inclusion Criteria:

• Must Be Over 20 Years Of Age, Regardless Of Sex
• Must Have A Diagnosis Of OA That Requiring Treatment
• Patients Must Have Taken an NSAID, Cox-2 Or Opioids On The Majority Of Days During The Last 4 Weeks Before Enrollment Who Are Intolerant (Due To Gastrointestinal Adverse Events) Or Inadequately Respond To Current Therapy (Vas >= 40 mm On A Pain Scale From 0-100 mm)
• Excluding Osteoarthritis, The Patient Is Judged To Be In Otherwise General Good Health Based On Medical History, Physical Examination, And Routine Laboratory Tests
• Must Agree To Participate Voluntarily In The Study
• Must Have The Capacity To Understand And Answer The Questionnaires Used In The Study
• Must Agree To Return For A Follow-Up Visit With The Treating Physician Four Weeks After The Initiation Of Treatment With Etoricoxib
• Patient Is Willing To Sign Informed Consent Form

Exclusion Criteria:

• Under 20 Years Of Age
• Severe Hepatic Insufficiency (Child-Pugh Score > 9)
• Advanced Renal Insufficiency (Creatinine Clearance < 30 Ml/Min)
• Any Contraindication Or Warning Or Precaution As Mentioned In The Approved Study Drug Package Insert
• Gi Ulcer With Active Bleeding Present At Study Enrollment
• Patient Has A Recent History Of Stroke, Myocardial Infarction Or Transient Ischemic Attack (Within The Previous 2 Years)